Search Results - "Vasilevskaya, Anna V."

Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study by Sokolova, Tatyana N., Solov'eva, Tatyana I., Aleksakhina, Svetlana N., Bolieva, Marina B., Goldberg, Viktor E., Kibisheva, Marianna V., Menshikov, Konstantin V., Ryazanov, Dmitrii V., Shkradyuk, Aleksandr V., Chapko, Yana S., Shchukina, Anna A., Khabriev, Idris M., Kirtbaya, Dmitrii V., Degtyarev, Alexey M., Epkhiev, Aleksandr A., Tyugina, Yana A., Togo, Aleksandr V., Murachuev, Mirza A., Ievleva, Aglaya G., Imyanitov, Evgenii N., Grechkina, Anna A., Stel'makh, Alena S., Odintsova, Svetlana V., Janus, Grigorii A., Musaeva, Khedi S., Chang, Victor L., Fateeva, Anastasia V., Startseva, Ekaterina P., Popova, Nataliya O., Mikheeva, Yulia V., Vasilevskaya, Anna V., Barbara, Victoria S., Khabibulaeva, Petimat I., Khlobystina, Alina G., Bembeeva, Ludmila V., Vladimirov, Vladimir I., Petrenko, Oleg L., Ruskova, Natalia G., Serikova, Ekaterina L., Subbotina, Ksenia S., Tkachenko, Svetlana A., Yukalchuk, Denis Y., Basova, Elena A., Stepanova, Mariya L., Erdniev, Sanal P., Goryainova, Alla, Gluzman, Mark I., Orlova, Rashida V., Stukan, Anastasiya I., Zukov, Ruslan A., Zyuzyukina, Alena V., Murunova, Yulia N., Sultanbaev, Aleksandr V., Vorobeva, Elena N., Mikhaevich, Leonid M., Lysenko, Anna N., Khachmamuk, Zarema K., Kozlov, Andrey E., Bakharev, Sergey Y., Pyliv, Victoria N., Amirkhanova, Irina K., Parsyan, Shahen G., Rossokha, Elena I., Osidze, Leri D., Shumskaya, Irina S., Agaeva, Anna V., Kasmynina, Tatiana A., Klimenko, Veronika V., Akhmetgareeva, Kamila T., Vakhitova, Almira A., Chakhkieva, Madina D., Udalova, Yana A., Dmitriev, Vadim N., Bakshun, Yana I., Vasilyev, Alexey E., Gasimly, Dunya D, Kravchenko, Nadezhda A., Maksimov, Dmitriy A., Nesterova, Alfia I., Khamgokov, Zaur M., Sharvashidze, Ineza O., Gadzaova, Christina H., Rakhmankulova, Galina G., Shvaiko, Kseniya A.

“…Background. By 2020, breast cancer (BC) has become the most frequent malignancy in the world. The most common type of BC is HR+/HER2-negative cancer,2540% of…”
Get full text

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice by Kolyadina, Irina V., Abidova, Natalia R., Akopyan, Arshak A., Antonova, Galina V., Arapova, Oksana I., Bobrova, Elvira A., Bolotina, Larisa V., Valiakhmetova, Chulpan K., Vasilevskaya, Anna V., Vladimirova, Lyubov Y., Volkonskiy, Mikhail V., Ganshina, Inna P., Gudkova, Irina E., Dergunov, Alexandr S., Evstigneeva, Irina V., Egurenkova, Viktoria S., Emshanov, Aleksei V., Zhukova, Lyudmila G., Zueva, Elena V., Karabina, Elena V., Kolokolov, James J., Kuzmicheva, Svetlana V., Kuchevskaya, Olesya A., Luev, Ivan A., Maistrenko, Ksenia S., Markizova, Elena V., Marfutov, Vasily V., Medvedev, Sergey P., Merzlikina, Yulia I., Nersesova, Tatyana A., Ovchinnikova, Elena G., Orlova, Svetlana A., Samaneva, Natalia Y., Stativko, Olesya A., Storozhakova, Anna E., Stroyakovskiy, Daniil L., Sultanbaev, Alexander V., Tekeeva, Asiat I., Fadeeva, Natalia V., Fedorova, Alina N., Shalaeva, Oksana M., Shangina, Irina A., Shirokova, Oksana N., Shumskikh, Alisa R., Yakubova, Mariam Z.

“…Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with…”
Get full text